Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.52 |
| ▸ | KDR | P35968 | 9/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.51 |
| ▸ | RAF1 | P04049 | 3/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | MST1R | Q04912 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028622 | 0.90 | MET (0.48) | BRAFKDRRAF1MST1RMET | |
| SCHEMBL11030933 | 0.90 | MST1R (0.51) | BRAFKDRMST1RMET | |
| SCHEMBL12873228 | 0.89 | MST1R (0.46) | BRAFKDRRAF1MST1RMET | |
| SCHEMBL11031964 | 0.89 | KDR (0.55) | BRAFKDRMST1RMET | |
| SCHEMBL1161052 | 0.89 | MST1R (0.47) | BRAFKDRRAF1MST1RMET | |
| SCHEMBL11028321 | 0.88 | BRD4 (0.49) | BRAFKDRRAF1MST1RMET | |
| SCHEMBL11034017 | 0.88 | MET (0.48) | KDRMST1RMET | |
| SCHEMBL11027452 | 0.87 | MST1R (0.44) | BRAFKDRMST1RMET | |
| SCHEMBL12873343 | 0.86 | MST1R (0.45) | BRAFKDRRAF1MST1RMET | |
| SCHEMBL11031594 | 0.86 | MET (0.49) | BRAFKDRMST1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2461869-B1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| WO-2011017142-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | CCNC, CCNI, CCNA1 | BRAF 582/4885KDR 2655/4885MAPK14 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.